Instrument Inactif

Autres langues PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam Autres places de cotation
- ^EUR	-

04/06	Pharming Group N.V. annonce l'acceptation par la FDA de la nouvelle soumission de la sNDA pour Joenja (leniolisib) dans le traitement des enfants de 4 à 11 ans atteints du syndrome APDS	CI
04/06	Pharming Group : la FDA accepte la demande de mise sur le marché d'un traitement contre l'immunodéficience	MT

Autres langues

03/07	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
03/07	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden
03/07	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
03/07	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden
07/06	Databedrijven blinken uit te midden van chipmalaise
05/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja to treat children aged 4 to 11 years with APDS
04/06	Pharming Group N.V. Announces U.S. FDA Acceptance of sNDA Resubmission for Joenja to Treat Children Aged 4 to 11 Years with APDS
04/06	Pharming Group Says Marketing Application for Immunodeficiency Disorder Drug Accepted by FDA
04/06	US FDA Accepts Pharming Group's Resubmitted Application for Immunodeficiency Treatment
04/06	Pharming: FDA accepteert herindiening Joenja
04/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
02/06	Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
28/05	Pharming Group announces results of 2026 Annual General Meeting of Shareholders
26/05	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
26/05	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
25/05	Pharming Group Receives EU Approval for Rare Primary Immunodeficiency Treatment Joenja
22/05	Pharming krijgt Europese goedkeuring voor Joenja
22/05	Pharming Says European Commission Grants Marketing Authorization to Joenja
22/05	European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union
22/05	Pharming Group Announces European Commission Grants Marketing Authorization For Joenja
19/05	Pharming N : Corporate Presentation - May 2026
15/05	Pharming N : 1Q 2026 financial results - Download transcript
10/05	Flinke koersbewegingen maar AEX per saldo slechts licht hoger
08/05	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden
08/05	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden